Assessment of

Autor: Rajesh, Chavan, Vineet, Zope, Nilesh, Chavan, Javeed, Shaikh, Kiran, Patil, Ravindra, Yeole, Sachin, Bhagwat, Mahesh, Patel
Rok vydání: 2020
Předmět:
Zdroj: Xenobiotica; the fate of foreign compounds in biological systems. 50(10)
ISSN: 1366-5928
Popis: WCK 771 (INN: levonadifloxacin) is a novel antibacterial agent belonging to benzoquinolizine subclass of fluoroquinolones which is under clinical development as a parenteral formulation and its prodrug WCK 2349 (INN: alalevonadifloxacin) as an oral option. Both the drugs have been approved recently in India based on phase III trial completed for ABSSSI.
Databáze: OpenAIRE